1. Nickerson HD, Dutta S. Diabetic complications: current challenges and opportunities. J Cardiovasc Transl Res. 2012; 5: 375-379. doi: 10.1007/s12265-012-9388-1
2. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382: 260-272. doi: 10.1016/S0140-6736(13)60687-X
3. Lim A. Diabetic nephropathy-complications and treatment. International journal of nephrology and renovascular disease. 2014; 7: 361-381. doi: 10.2147/IJNRD.S40172
4. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010; 21: 556-563. doi: 10.1681/ASN.2010010010
5. Mora-Fernandez C, Dominguez-Pimentel V, de Fuentes MM, et al. Diabetic kidney disease: from physiology to therapeutics. J Physiol. 2014; 592: 3997-4012. doi: 10.1113/jphysiol.2014.272328
6. Badal SS, Danesh FR. New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis. 2014; 63: S63-S83. doi: 10.1053/j.ajkd.2013.10.047
7. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiological reviews. 2013; 93: 137-188. doi: 10.1152/physrev.00045.2011
8. Chan GC, Tang SC. Diabetic nephropathy: landmark clinical trials and tribulations. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 2015. doi: 10.1093/ndt/gfu411
9. Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic nephropathy: diagnosis and treatment. Nature reviews. Endocrinology. 2013; 9: 713-723. doi: 10.1038/nrendo.2013.184
10. Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. Nature reviews. Nephrology. 2014; 10: 493-503. doi:10.1038/nrneph.2014.114
11. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clinical science. 2013; 124: 139-152. doi: 10.1042/CS20120198
12. Gomez IG, Grafals M, Portilla D, Duffield JS. MicroRNAs as potential therapeutic targets in kidney disease. Journal of the Formosan Medical Association=Taiwan yi zhi. 2013; 112: 237-243. doi: 10.1016/j.jfma.2012.12.011
13. Li R, Chung AC, Yu X, Lan HY. MicroRNAs in Diabetic Kidney Disease. International journal of endocrinology. 2014; 2014: 593956. doi: 10.1155/2014/593956
14. Khella HW, Bakhet M, Lichner Z, et al. MicroRNAs in kidney disease: an emerging understanding. Am J Kidney Dis. 2013; 61: 798-808. doi: 10.1053/j.ajkd.2012.09.018
15. Schena FP, Serino G, Sallustio F. MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association. 2014; 29: 755-763. doi: 10.1093/ndt/gft223
16. Srivastava SP, Koya D, Kanasaki K. MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT. BioMed research international. 2013; 2013: 125469. doi: 10.1155/2013/125469
17. Tanaka Y, Kume S, Kitada M, et al. Autophagy as a therapeutic target in diabetic nephropathy. Experimental diabetes research. 2012; 2012: 628978. doi: 10.1155/2012/628978
18. Fang L, Zhou Y, Cao H, et al. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PloS one. 2013; 8: e60546. doi: 10.1371/ journal.pone.0060546
19. Ding Y, Choi ME. Autophagy in diabetic nephropathy. The Journal of endocrinology. 2015; 224: R15-R30. doi: 10.1530/JOE-14-0437
20. Wang Z, Choi ME. Autophagy in kidney health and disease. Antioxid Redox Signal. 2014; 20: 519-537. doi: 10.1089/ars.2013.5363
21. Kume S, Yamahara K, Yasuda M, et al. Autophagy: Emerging Therapeutic Target for Diabetic Nephropathy. Semin Nephrol. 2014; 34: 9-16. doi: 10.1016/j.semnephrol.2013.11.003
22. Kelly KJ, Liu Y, Zhang J, et al. Comprehensive genomic profiling in diabetic nephropathy reveals the predominance of proinflammatory pathways. Physiological genomics. 2013; 45: 710-719. doi: 10.1152/physiolgenomics.00028.2013
23. Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators of inflammation. 2012; 2012: 146154. doi: 10.1155/2012/146154
24. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nature reviews. Immunology. 2013; 13: 397-411. doi: 10.1038/nri3452
25. Baroja-Mazo A, Martin-Sanchez F, Gomez AI, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nature immunology. 2014; 15: 738-748. doi: 10.1038/ni.2919
26. Ozaki E, Campbell M, Doyle SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. Journal of inflammation research. 2015; 8: 15-27. doi: 10.2147/JIR.S51250
27. Vilaysane A, Chun J, Seamone ME, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010; 21: 1732-1744. doi: 10.1681/asn.2010020143
28. Shahzad K, Bock F, Dong W, et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 2015; 87: 74-84. doi: 10.1038/ki.2014.271
29. Chang A, Ko K, Clark MR. The emerging role of the inflammasome in kidney diseases. Current opinion in nephrology and hypertension. 2014; 23: 204-210. doi: 10.1097/01.mnh.0000444814.49755.90
30. McClelland AD, Kantharidis P. microRNA in the development of diabetic complications. Clinical science. 2014; 126: 95-110. doi: 10.1042/CS20130079
31. Wu H, Kong L, Zhou S, et al. The role of microRNAs in diabetic nephropathy. Journal of diabetes research. 2014; 2014: 920134. doi: 10.1155/2014/920134
32. Putta S, Lanting L, Sun G, et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2012; 23: 458-469. doi: 10.1681/ASN.2011050485
33. Wang B, Komers R, Carew R, et al. Suppression of microRNA-29 Expression by TGF-beta1 Promotes Collagen Expression and Renal Fibrosis. J Am Soc Nephrol. 2012; 23: 252-265. doi: 10.1681/ASN.2011010055
34. Wang B, Koh P, Winbanks C, et al. miR-200a Prevents Renal Fibrogenesis Through Repression of TGF-{beta}2 Expression. Diabetes. 2011; 60: 280-287. doi: 10.2337/db10-0892
35. Zhong X, Chung AC, Chen HY, et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia. 2013; 56: 663-674. doi: 10.1007/s00125-012-2804-x
36. Wang JY, Gao YB, Zhang N, et al. miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Molecular and cellular endocrinology. 2014; 392: 163-172. doi: 10.1016/j.mce.2014.05.018
37. Lai JY, Luo J, O’Connor C, et al. MicroRNA-21 in Glomerular Injury. J Am Soc Nephrol. 2015; 26: 805-816. doi: 10.1681/ASN.2013121274
38. Krupa A, Jenkins R, Luo DD, et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol. 2010; 21: 438-447. doi: 10.1681/ASN.2009050530
39. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol. 2009; 20: 2493-2502. doi: 10.1681/ASN.2008111186
40. Kitada M, Kume S, Takeda-Watanabe A, et al. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clinical science. 2013; 124: 153-164. doi: 10.1042/CS20120190
41. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Molecular cell. 2010; 40: 280-293. doi: 10.1016/j.molcel.2010.09.023
42. Zhan M, Brooks C, Liu F, et al. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int. 2013; 83: 568-581. doi: 10.1038/ki.2012.441
43. Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J. 2012; 441: 523-540. doi: 10.1042/BJ20111451
44. Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell death and differentiation. 2013; 20: 31-42. doi: 10.1038/cdd.2012.81
45. Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013; 24: 1901-1912. doi: 10.1681/ASN.2013020126
46. Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? British journal of pharmacology. 2014; 171: 1917-1942. doi: 10.1111/bph.12503